A leading remote cardiac monitoring player

LifeWatch specialises in ECG-based remote cardiac monitoring services and is one of the leading companies in this space in the US, with around four million patients monitored to date. The company had a solid FY15, with 8.3% adjusted revenue growth and its strongest EBITDA in six years. However, 2016 was turbulent, mainly as a result of costly but one-off legal settlements. Having streamlined its cost base and left the legacy issues behind it, LifeWatch is now well placed to capitalise on healthy market growth, returning to profitability in FY17; we value it at CHF258m ($250m).